{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,13]],"date-time":"2025-11-13T12:35:04Z","timestamp":1763037304923},"reference-count":34,"publisher":"Springer Science and Business Media LLC","issue":"5","license":[{"start":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T00:00:00Z","timestamp":1553040000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Internist"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1007\/s00108-019-0588-5","type":"journal-article","created":{"date-parts":[[2019,3,20]],"date-time":"2019-03-20T15:02:57Z","timestamp":1553094177000},"page":"432-439","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Immunglobulin-A-Nephropathie"],"prefix":"10.1007","volume":"60","author":[{"given":"C.","family":"Seikrit","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"T.","family":"Rauen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Floege","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,20]]},"reference":[{"key":"588_CR1","doi-asserted-by":"publisher","first-page":"3620","DOI":"10.1093\/ndt\/gfp441","volume":"24","author":"J Barratt","year":"2009","unstructured":"Barratt J, Eitner F, Feehally J et\u00a0al (2009) Immune complex formation in IgA nephropathy: A\u00a0case of the \u2018right\u2019 antibodies in the \u2018wrong\u2019 place at the \u2018wrong\u2019 time? Nephrol Dial Transplant 24:3620\u20133623","journal-title":"Nephrol Dial Transplant"},{"key":"588_CR2","first-page":"694","volume":"74","author":"J Berger","year":"1968","unstructured":"Berger J, Hinglais N (1968) Intercapillary deposits of IgA-IgG. J\u00a0D\u2019urol Nephrol 74:694\u2013695","journal-title":"J D\u2019urol Nephrol"},{"key":"588_CR3","doi-asserted-by":"publisher","first-page":"752","DOI":"10.1681\/ASN.2010040355","volume":"22","author":"F Berthoux","year":"2011","unstructured":"Berthoux F, Mohey H, Laurent B et\u00a0al (2011) Predicting the risk for dialysis or death in IgA nephropathy. J\u00a0Am Soc Nephrol 22:752\u2013761","journal-title":"J Am Soc Nephrol"},{"key":"588_CR4","doi-asserted-by":"publisher","first-page":"67","DOI":"10.3920\/BM2012.0024","volume":"4","author":"P Brandtzaeg","year":"2013","unstructured":"Brandtzaeg P (2013) Gate-keeper function of the intestinal epithelium. Benef Microbes 4:67\u201382","journal-title":"Benef Microbes"},{"key":"588_CR5","doi-asserted-by":"publisher","first-page":"1870","DOI":"10.1001\/jama.2018.4930","volume":"319","author":"WF Clark","year":"2018","unstructured":"Clark WF, Sontrop JM, Huang SH et\u00a0al (2018) Effect of coaching to increase water intake on kidney function decline in adults with chronic kidney disease: The CKD WIT randomized clinical trial. JAMA 319:1870\u20131879","journal-title":"JAMA"},{"key":"588_CR6","doi-asserted-by":"publisher","first-page":"504","DOI":"10.1016\/j.semnephrol.2018.05.020","volume":"38","author":"R Coppo","year":"2018","unstructured":"Coppo R (2018) The gut-renal connection in IgA Nephropathy. Semin Nephrol 38:504\u2013512","journal-title":"Semin Nephrol"},{"key":"588_CR7","doi-asserted-by":"publisher","DOI":"10.1093\/ndt\/gfy338","author":"R Coppo","year":"2018","unstructured":"Coppo R (2018) Towards a\u00a0personalized treatment for IgA nephropathy considering pathology and pathogenesis. Nephrol Dial Transplant. \n                    https:\/\/doi.org\/10.1093\/ndt\/gfy338","journal-title":"Nephrol Dial Transplant"},{"key":"588_CR8","doi-asserted-by":"publisher","first-page":"301","DOI":"10.1038\/nrneph.2012.42","volume":"8","author":"P Cravedi","year":"2012","unstructured":"Cravedi P, Ruggenenti P, Remuzzi G (2012) Proteinuria should be used as a\u00a0surrogate in CKD. Nat Rev Nephrol 8:301\u2013306","journal-title":"Nat Rev Nephrol"},{"key":"588_CR9","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s40620-015-0245-6","volume":"29","author":"MR Daha","year":"2016","unstructured":"Daha MR, Van Kooten C (2016) Role of complement in IgA nephropathy. J\u00a0Nephrol 29:1\u20134","journal-title":"J Nephrol"},{"key":"588_CR10","doi-asserted-by":"publisher","first-page":"2117","DOI":"10.1016\/S0140-6736(17)30550-0","volume":"389","author":"BC Fellstrom","year":"2017","unstructured":"Fellstrom BC, Barratt J, Cook H et al (2017) Targeted-release budesonide versus placebo in patients with IgA nephropathy (NEFIGAN): A\u00a0double-blind, randomised, placebo-controlled phase 2b trial. Lancet 389:2117\u20132127","journal-title":"Lancet"},{"key":"588_CR11","doi-asserted-by":"publisher","first-page":"1277","DOI":"10.1007\/s00108-015-3781-1","volume":"56","author":"J Floege","year":"2015","unstructured":"Floege J (2015) Glomerulonephritides. Internist (Berl) 56:1277\u20131285","journal-title":"Internist (Berl)"},{"key":"588_CR12","doi-asserted-by":"publisher","first-page":"992","DOI":"10.1053\/j.ajkd.2011.05.033","volume":"58","author":"J Floege","year":"2011","unstructured":"Floege J (2011) The pathogenesis of IgA nephropathy: What is new and how does it change therapeutic approaches? Am J Kidney Dis 58:992\u20131004","journal-title":"Am J Kidney Dis"},{"issue":"12","key":"588_CR13","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1007\/s00108-018-0500-8","volume":"59","author":"J Floege","year":"2018","unstructured":"Floege J, Boor P, Moeller MJ (2018) What is certain in the treatment of glomerulonephritis? Internist (Berl) 59(12):1268\u20131278. \n                    https:\/\/doi.org\/10.1007\/s00108-018-0500-8","journal-title":"Internist (Berl)"},{"key":"588_CR14","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.kint.2018.03.009","volume":"94","author":"J Floege","year":"2018","unstructured":"Floege J, Daha MR (2018) IgA nephropathy: New insights into the role of complement. Kidney Int 94:16\u201318","journal-title":"Kidney Int"},{"key":"588_CR15","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1038\/nrneph.2015.208","volume":"12","author":"J Floege","year":"2016","unstructured":"Floege J, Feehally J (2016) The mucosa-kidney axis in IgA nephropathy. Nat Rev Nephrol 12:147\u2013156","journal-title":"Nat Rev Nephrol"},{"key":"588_CR16","doi-asserted-by":"publisher","first-page":"320","DOI":"10.1038\/nrneph.2013.59","volume":"9","author":"J Floege","year":"2013","unstructured":"Floege J, Feehally J (2013) Treatment of IgA nephropathy and Henoch-Schonlein nephritis. Nat Rev Nephrol 9:320\u2013327","journal-title":"Nat Rev Nephrol"},{"key":"588_CR17","doi-asserted-by":"publisher","first-page":"2139","DOI":"10.1093\/ndt\/gfh974","volume":"20","author":"G Frisch","year":"2005","unstructured":"Frisch G, Lin J, Rosenstock J et al (2005) Mycophenolate mofetil (MMF) vs placebo in patients with moderately advanced IgA nephropathy: A\u00a0double-blind randomized controlled trial. Nephrol Dial Transplant 20:2139\u20132145","journal-title":"Nephrol Dial Transplant"},{"key":"588_CR18","doi-asserted-by":"publisher","first-page":"c86","DOI":"10.1159\/000213086","volume":"112","author":"K Kaartinen","year":"2009","unstructured":"Kaartinen K, Niemela O, Syrjanen J et\u00a0al (2009) Alcohol consumption and kidney function in IgA glomerulonephritis. Nephron Clin Pract 112:c86\u2013c93","journal-title":"Nephron Clin Pract"},{"key":"588_CR19","doi-asserted-by":"publisher","first-page":"2325","DOI":"10.1172\/JCI74475","volume":"124","author":"K Kiryluk","year":"2014","unstructured":"Kiryluk K, Novak J (2014) The genetics and immunobiology of IgA nephropathy. J\u00a0Clin Invest 124:2325\u20132332","journal-title":"J Clin Invest"},{"key":"588_CR20","doi-asserted-by":"publisher","first-page":"1841","DOI":"10.1093\/ndt\/gfx242","volume":"32","author":"T Knoop","year":"2017","unstructured":"Knoop T, Vikse BE, Mwakimonga A, Leh S, Bj\u00f8rneklett R (2017) Long-term outcome in 145 patients with assumed benign immunoglobulin A nephropathy. Nephrol Dial Transplant 32:1841\u20131850","journal-title":"Nephrol Dial Transplant"},{"key":"588_CR21","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1681\/ASN.2016060640","volume":"28","author":"RA Lafayette","year":"2017","unstructured":"Lafayette RA, Canetta PA, Rovin BH et\u00a0al (2017) A randomized, controlled trial of Rituximab in IgA Nephropathy with Proteinuria and renal dysfunction. J\u00a0Am Soc Nephrol 28:1306\u20131313","journal-title":"J Am Soc Nephrol"},{"key":"588_CR22","doi-asserted-by":"publisher","first-page":"432","DOI":"10.1001\/jama.2017.9362","volume":"318","author":"J Lv","year":"2017","unstructured":"Lv J, Zhang H, Wong MG et\u00a0al (2017) Effect of oral Methylprednisolone on clinical outcomes in patients with IgA Nephropathy: The TESTING randomized clinical trial. JAMA 318:432\u2013442","journal-title":"JAMA"},{"key":"588_CR23","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.it.2015.06.006","volume":"36","author":"AJ Macpherson","year":"2015","unstructured":"Macpherson AJ, Koller Y, Mccoy KD (2015) The bilateral responsiveness between intestinal microbes and IgA. Trends Immunol 36:460\u2013470","journal-title":"Trends Immunol"},{"key":"588_CR24","doi-asserted-by":"publisher","first-page":"1669","DOI":"10.1038\/ki.1997.232","volume":"51","author":"SR Orth","year":"1997","unstructured":"Orth SR, Ritz E, Schrier RW (1997) The renal risks of smoking. Kidney Int 51:1669\u20131677","journal-title":"Kidney Int"},{"key":"588_CR25","doi-asserted-by":"publisher","first-page":"1783","DOI":"10.1681\/ASN.2010010117","volume":"21","author":"C Pozzi","year":"2010","unstructured":"Pozzi C, Andrulli S, Pani A et\u00a0al (2010) Addition of azathioprine to corticosteroids does not benefit patients with IgA nephropathy. J\u00a0Am Soc Nephrol 21:1783\u20131790","journal-title":"J Am Soc Nephrol"},{"key":"588_CR26","doi-asserted-by":"publisher","first-page":"2225","DOI":"10.1056\/NEJMoa1415463","volume":"373","author":"T Rauen","year":"2015","unstructured":"Rauen T, Eitner F, Fitzner C et\u00a0al (2015) Intensive Supportive Care plus Immunosuppression in IgA Nephropathy. N\u00a0Engl J Med 373:2225\u20132236","journal-title":"N Engl J Med"},{"key":"588_CR27","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1681\/ASN.2017060713","volume":"29","author":"T Rauen","year":"2018","unstructured":"Rauen T, Fitzner C, Eitner F et\u00a0al (2018) Effects of two immunosuppressive treatment protocols for IgA Nephropathy. J\u00a0Am Soc Nephrol 29:317\u2013325","journal-title":"J Am Soc Nephrol"},{"key":"588_CR28","doi-asserted-by":"publisher","first-page":"546","DOI":"10.1038\/ki.2009.168","volume":"76","author":"IS Roberts","year":"2009","unstructured":"Roberts IS, Cook HT, Troyanov S et\u00a0al (2009) The Oxford classification of IgA nephropathy: Pathology definitions, correlations, and reproducibility. Kidney Int 76:546\u2013556","journal-title":"Kidney Int"},{"key":"588_CR29","doi-asserted-by":"publisher","first-page":"973","DOI":"10.2215\/CJN.02300215","volume":"11","author":"C Sarcina","year":"2016","unstructured":"Sarcina C, Tinelli C, Ferrario F et\u00a0al (2016) Changes in Proteinuria and side effects of Corticosteroids alone or in combination with Azathioprine at different stages of IgA Nephropathy. Clin J Am Soc Nephrol 11:973\u2013981","journal-title":"Clin J Am Soc Nephrol"},{"issue":"1","key":"588_CR30","doi-asserted-by":"publisher","first-page":"328","DOI":"10.1186\/s12882-018-1128-6","volume":"19","author":"JI Schimpf","year":"2018","unstructured":"Schimpf JI, Klein T, Fitzner C et al (2018) Renal outcomes of STOP-IgAN trial patients in relation to baseline histology (MEST-C scores). BMC Nephrol 19(1):328. \n                    https:\/\/doi.org\/10.1186\/s12882-018-1128-6","journal-title":"BMC Nephrol"},{"key":"588_CR31","volume-title":"3000 free medical images","author":"Servier","year":"2018","unstructured":"Servier (2018) 3000 free medical images. \n                    https:\/\/smart.servier.com\/\n                    \n                  . Zugegriffen: 7. Jan. 2019"},{"key":"588_CR32","doi-asserted-by":"publisher","first-page":"1795","DOI":"10.1681\/ASN.2011050464","volume":"22","author":"H Suzuki","year":"2011","unstructured":"Suzuki H, Kiryluk K, Novak J et\u00a0al (2011) The pathophysiology of IgA nephropathy. J\u00a0Am Soc Nephrol 22:1795\u20131803","journal-title":"J Am Soc Nephrol"},{"key":"588_CR33","doi-asserted-by":"publisher","first-page":"2745","DOI":"10.1681\/ASN.2018010091","volume":"29","author":"H Trachtman","year":"2018","unstructured":"Trachtman H, Nelson P, Adler S et\u00a0al (2018) DUET: A phase 2 study evaluating the efficacy and safety of Sparsentan in patients with FSGS. J\u00a0Am Soc Nephrol 29:2745\u20132754","journal-title":"J Am Soc Nephrol"},{"key":"588_CR34","doi-asserted-by":"publisher","first-page":"1014","DOI":"10.1016\/j.kint.2017.02.003","volume":"91","author":"H Trimarchi","year":"2017","unstructured":"Trimarchi H, Barratt J, Cattran DC et\u00a0al (2017) Oxford classification of IgA nephropathy 2016: an update from the IgA Nephropathy classification working group. Kidney Int 91:1014\u20131021","journal-title":"Kidney Int"}],"container-title":["Der Internist"],"original-title":[],"language":"de","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00108-019-0588-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00108-019-0588-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,3,19]],"date-time":"2020-03-19T00:33:02Z","timestamp":1584577982000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00108-019-0588-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,20]]},"references-count":34,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2019,5]]}},"alternative-id":["588"],"URL":"https:\/\/doi.org\/10.1007\/s00108-019-0588-5","relation":{},"ISSN":["0020-9554","1432-1289"],"issn-type":[{"value":"0020-9554","type":"print"},{"value":"1432-1289","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,20]]},"assertion":[{"value":"20 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Einhaltung ethischer Richtlinien"}},{"value":"J.\u00a0Floege war in den letzten 4\u00a0Jahren beratend f\u00fcr Pharmalink (Nefecon-Studie) t\u00e4tig. C.\u00a0Seikrit und T.\u00a0Rauen geben an, dass kein Interessenkonflikt besteht.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}},{"value":"Dieser Beitrag beinhaltet keine von den Autoren durchgef\u00fchrten Studien an Menschen oder Tieren.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Interessenkonflikt"}}]}}